Press Releases

Initiator Pharma A/S, a clinical-stage biotech company, today announced that its Clinical Trial Application (CTA) for a planned Phase 2a clinical proof-of-concept study in women with vulvodynia has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and a local ethics committee. First patients are expected to be enrolled in Q4 2025.

Initiator Pharma A/S, a clinical-stage biotech company, today announces that its CEO, Claus Elsborg Olesen, will present and together with Julia Persson, Founder of HappyLongevity and AI-Augmented Venture Designer, co-lead a session focused on health innovation at the upcoming Nordic Women’s Health Hub, taking place on September 8, 2025, 10.00–17.00 at Fællessalen, Christiansborg, Copenhagen, Denmark.

Initiator Pharma A/S, a clinical-stage biotech company, has submitted a clinical trial application (CTA) to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), and local ethics committee in the UK for the approval to conduct a Phase 2a clinical proof-of-concept study in women suffering from vulvodynia, a severe chronic pain condition affecting approximately 10 percent of women worldwide. The study will be conducted together with MAC Clinical Research in the UK.

Initiator Pharma’s Remuneration Report 2024 has now been published and is available on the company ́s home page.